Key statistics
As of last trade Moleculin Biotech Inc (MOL:FRA) traded at 0.43, 0.00% above its 52-week low of 0.43, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.43 |
Low | 0.43 |
Bid | -- |
Offer | -- |
Previous close | 0.43 |
Average volume | -- |
---|---|
Shares outstanding | 2.84m |
Free float | 2.74m |
P/E (TTM) | -- |
Market cap | 7.25m USD |
EPS (TTM) | -11.62 USD |
Data delayed at least 15 minutes, as of Mar 21 2024 19:48 BST.
More ▼
Press releases
- Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
- Moleculin to Present at Two Upcoming Investor Conferences
- Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
- Moleculin Participates in Virtual Investor "What this Means" Segment
- Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
- Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
- Moleculin Announces Closing of up to $16.5 Million Public Offering
- Moleculin Announces Pricing of up to $16.5 Million Public Offering
- Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
More ▼